<code id='CFCCDA8EF1'></code><style id='CFCCDA8EF1'></style>
    • <acronym id='CFCCDA8EF1'></acronym>
      <center id='CFCCDA8EF1'><center id='CFCCDA8EF1'><tfoot id='CFCCDA8EF1'></tfoot></center><abbr id='CFCCDA8EF1'><dir id='CFCCDA8EF1'><tfoot id='CFCCDA8EF1'></tfoot><noframes id='CFCCDA8EF1'>

    • <optgroup id='CFCCDA8EF1'><strike id='CFCCDA8EF1'><sup id='CFCCDA8EF1'></sup></strike><code id='CFCCDA8EF1'></code></optgroup>
        1. <b id='CFCCDA8EF1'><label id='CFCCDA8EF1'><select id='CFCCDA8EF1'><dt id='CFCCDA8EF1'><span id='CFCCDA8EF1'></span></dt></select></label></b><u id='CFCCDA8EF1'></u>
          <i id='CFCCDA8EF1'><strike id='CFCCDA8EF1'><tt id='CFCCDA8EF1'><pre id='CFCCDA8EF1'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:3313
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          Startup Neumora takes a novel depression drug to Phase 3
          Startup Neumora takes a novel depression drug to Phase 3

          AdobeNeumora,aprivatelyheldbiotechcompany,ismovingintothefinalphaseoftestingwithanoveltreatmentforde

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Google and Epic fight stronger regulation of AI in health care

          AdobeBigbusinessespoisedtoprofitfromtheadvanceofartificialintelligenceinhealthcarearepushingbackagai